Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN-101 in Aicardi-Goutières Syndrome (AGS)
NCT05613868Phase 2Terminated
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of censavudine in Aicardi-Goutières syndrome (AGS), sponsored by Transposon Therapeutics, Inc. Primary endpoints: Change in innate immune signaling at 48 weeks and Incidence and severity of spontaneously reported treatment-emergent adverse events at 48 weeks. Started Mar 2023; status: terminated.
02
Drugs
censavudine
03
Conditions
Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on NCT05613868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613868.